ReN-1820
ReN-1820 is an investigational drug currently under development for the treatment of neurodegenerative disorders. It is a small molecule that has shown promise in preclinical studies for its potential neuroprotective and neurorestorative properties. ReN-1820 is being studied primarily for its effects on Alzheimer's disease and Parkinson's disease, two of the most common neurodegenerative conditions.
Mechanism of Action[edit | edit source]
ReN-1820 is believed to exert its effects through modulation of the neurotrophic factors and enhancement of synaptic plasticity. It has been shown to increase the expression of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), which are critical for the survival and function of neurons. Additionally, ReN-1820 may inhibit the aggregation of amyloid-beta peptides, a hallmark of Alzheimer's disease pathology.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of ReN-1820 is characterized by its high oral bioavailability and moderate half-life, allowing for convenient dosing schedules. It is metabolized primarily in the liver and excreted via the renal route. Studies have shown that ReN-1820 crosses the blood-brain barrier, which is essential for its action in the central nervous system.
Clinical Trials[edit | edit source]
ReN-1820 is currently in Phase II clinical trials. Early results have indicated a favorable safety profile and potential efficacy in improving cognitive function in patients with mild to moderate Alzheimer's disease. Ongoing studies are evaluating its long-term effects and potential benefits in other neurodegenerative conditions.
Potential Side Effects[edit | edit source]
While generally well-tolerated, some patients have reported mild gastrointestinal disturbances and headaches. As with any investigational drug, further studies are needed to fully understand the safety profile of ReN-1820.
Research and Development[edit | edit source]
ReN-1820 was developed by a collaboration between academic institutions and pharmaceutical companies. The research is funded by grants from various health organizations and government bodies. The development of ReN-1820 is part of a broader effort to address the unmet medical needs in neurodegenerative diseases.
Also see[edit | edit source]
- Neurodegenerative disease
- Alzheimer's disease
- Parkinson's disease
- Neurotrophic factors
- Brain-derived neurotrophic factor
Template:Neuropharmacology footer
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
